CALCA, CALCB: Calcitonin gene-related peptide
Family in Homo sapiens that 3 drugs act on.
- Drugs that act on it: 3
- Approved: 3
- In phases 1 to 3: 0
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on CALCA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 3
| Eptinezumab | Approved | Lundbeck | Antibody | InhibitorCalcitonin gene-related peptide inhibitor | 16 |
| Fremanezumab | Approved | Teva Pharmaceutical Industries | Antibody | AntagonistCalcitonin gene-related peptide antagonist | 11 |
| Galcanezumab | Approved | Eli Lilly | Antibody | InhibitorCalcitonin gene-related peptide inhibitor | 10 |
| Migraine Menopause Study | Eptinezumab | Phase 4 | Not yet recruiting | Alberta Neurologic Centre | Nov 4, 2026 |
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) | Fremanezumab | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | Sep 21, 2026 |
| Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) | Eptinezumab, Fremanezumab, Galcanezumab | Phase 4 | Not yet recruiting | Stanford University | Jun 17, 2026 |
| Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness | Fremanezumab | Phase 4 | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | Jun 17, 2026 |
| Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension | Eptinezumab | Phase 3 | Not yet recruiting | Rigmor Højland Jensen | Jun 12, 2026 |
| Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease | Galcanezumab | Early phase 1 | Recruiting | Xuanwu Hospital, Beijing | Jan 7, 2026 |
| Treatment of Atypical Resistant Facial Pain | Eptinezumab | — | Enrolling by invitation | Alenka Spindler-Vesel | Nov 26, 2025 |
| Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | Eptinezumab | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | Sep 24, 2025 |
| Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine | Eptinezumab, Fremanezumab, Galcanezumab | — | Recruiting | Hospital Universitari Vall d'Hebron Research Institute | Sep 8, 2025 |
| i-NEED: NEw migrainE Drugs Database | Eptinezumab, Fremanezumab, Galcanezumab | — | Recruiting | IRCCS San Raffaele Roma | Aug 5, 2025 |
| New Methods for Evaluating Preventive Migraine Treatment | Fremanezumab | Not applicable | Recruiting | University of Aarhus | Jul 17, 2025 |
| Fremanezumab for the Prevention of Menstrually-related Migraine Attacks | Fremanezumab | — | Recruiting | Insel Gruppe AG, University Hospital Bern | Oct 26, 2024 |
| The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) | Eptinezumab | — | Recruiting | University of Florence | Oct 8, 2024 |
| Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies | Fremanezumab, Galcanezumab | — | Active, not recruiting | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Jun 14, 2024 |
| Migraine Medication Effects on Urinary Symptoms | Galcanezumab | — | Enrolling by invitation | The Cleveland Clinic | Jan 19, 2024 |
| Emgality for Migraine in Breastmilk | Galcanezumab | — | Recruiting | University of California, San Francisco | Oct 16, 2023 |
| CGRP Inhibition, Autonomic Function, and Migraine | Galcanezumab | — | Recruiting | Medical University of Vienna | Nov 13, 2020 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3832947, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets